Translation News and Research

RSS

National Jewish Health issued method patent for desensitizing B cells

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.

19 Jan 2011

ICON announces acquisition of Oxford Outcomes

ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the expansion of its Late Phase and Outcomes Research services through the acquisition of Oxford Outcomes, a leading international health outcomes consultancy.

14 Jan 2011

Sanofi-aventis, UCSF announce research and development collaborations

Sanofi-aventis and the University of California, San Francisco (UCSF) announced today that they have formed two research and development collaborations that join together leaders from academia and industry to more rapidly advance groundbreaking innovation from the lab to the patient.

13 Jan 2011

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded two preclinical services contracts totaling $17.4 million by the National Heart, Lung, and Blood Institute, one of the National Institutes of Health.

13 Jan 2011

Study supports use of telomerase inhibitors for treatment of childhood cancers

Geron Corporation today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, selectively targets cancer stem cells in pediatric tumors of neural origin.

11 Jan 2011

Research suggests novel therapeutic approach for Huntington's Disease

Hope for new ways of treating devastating neurodegenerative disorders such as Huntington's disease has been raised by a trans-Atlantic team of researchers thanks to the use of cutting-edge genetic techniques.

10 Jan 2011

Researchers demystify death of brain cells in Parkinson's patients

Just 5 percent of Parkinson's disease cases can be explained by genetic mutation, while the rest have no known cause. But a new discovery by researchers at The University of Texas Health Science Center San Antonio may begin to explain why the vast majority of Parkinson's patients develop the progressive neurodegenerative disease.

10 Jan 2011

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, today presented new clinical data from its ALN-VSP Phase I liver cancer trial in a presentation at the Dana-Farber Cancer Institute in Boston. Results from molecular analysis of human biopsy samples showed achievement of pharmacologically relevant siRNA drug levels in tissues.

5 Jan 2011

ACT, Roslin Cells collaborate to establish hESC line bank using single-ceblastomere technique

Advanced Cell Technology, a leader in the field of regenerative medicine, announced today that it has entered into a Memorandum of Understanding with Roslin Cells LTD of Scotland, in which the two companies contemplate a definitive collaboration agreement in the near future.

28 Dec 2010

Demand for medical interpreters to increase in the new year

As the number of non-English speakers seeking healthcare in the United States continues to grow, so does the need for medical interpreters who can serve as a liaison between patients and their doctors. The demand for medical interpreters is expected to increase even more when new standards go into effect on January 1, 2011 requiring healthcare organizations to provide an interpreter to patients who speak limited English.

24 Dec 2010

BioTime enters MTA with UC to make research-grade hES cell lines

BioTime, Inc. today announced a material transfer agreement (MTA) with the University of California (UC) system to make five research-grade human embryonic stem (hES) cell lines available to UC system researchers. These lines are genetically identical to a bank of GMP-compliant hES cell lines that will be made available to California-based researchers under a recent agreement between BioTime and the California Institute for Regenerative Medicine (CIRM).

23 Dec 2010

NIH Clinical Center opens doors to Damon Runyon Clinical Investigators

A new pilot partnership between the National Institutes of Health Clinical Center, the National Cancer Institute's Center for Cancer Research, and the Damon Runyon Cancer Research Foundation will offer some of the capabilities and expertise of America's research hospital to an external group of clinical investigators in cancer research. The special talent and resources of the NIH will allow Damon Runyon-funded investigators to undertake studies and collaborations that will advance understanding of the prevention, diagnosis, and treatment of cancer.

22 Dec 2010

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, presented new data at the 2010 International Chemical Congress of Pacific Basin Societies, being held in Honolulu, Hawaii, December 15-20.

17 Dec 2010

UCSF physicians evlaute devices that could reduce hair loss in breast cancer patients undergoing chemotherapy

UCSF physicians are combating a devastating side effect of chemotherapy with an innovative new program -- "Hair to Stay" -- to evaluate devices that could reduce scalp hair loss in breast cancer patients.

14 Dec 2010

ORNL's software scans molecular databases, may help scientists to develop new drug treatments

A quicker and cheaper technique to scan molecular databases developed at the Department of Energy's Oak Ridge National Laboratory could put scientists on the fast track to developing new drug treatments.

13 Dec 2010

NCCN announces new guidelines for patients with multiple myeloma

The National Comprehensive Cancer Network recently announced the latest addition to the library of NCCN Guidelines for Patients, the NCCN Guidelines for Patients: Multiple Myeloma. This new resource is a patient-friendly translation of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma, which physicians use when determining appropriate cancer treatment.

10 Dec 2010

Dartmouth awarded $2M grant for new Children's Environmental Health and Disease Prevention Center

Dartmouth recently received a $2 million pilot grant to fund the new Children's Environmental Health and Disease Prevention Center at Dartmouth. The grant is jointly funded by the United States Environmental Protection Agency (EPA) and the National Institute for Environmental Health Sciences (NIEHS). Dartmouth's is one of six emerging centers nationally that are undertaking interdisciplinary research to assist public health professionals and policy makers in combating children's diseases caused by environment pollutants.

7 Dec 2010

UBC receives $7M grant from Bill & Melinda Gates Foundation for PRE-EMPT Project

The University of British Columbia has received a $7 million grant from the Bill & Melinda Gates Foundation. UBC researchers working at the Child & Family Research Institute will test new strategies for the monitoring, prevention, and treatment of pre-eclampsia.

4 Dec 2010

BRI enters 3-year partnership with Roche to develop human immunology programs

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced that it has formed a three-year partnership with Roche to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.